FDA gives nod to first once-daily protease inhibitor
Tags: PROTEASE inhibitors -- Therapeutic use; ANTIRETROVIRAL agents
Related Articles
- Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. Torti, Carlo; Lapadula, Giuseppe; Casari, Salvatore; Puoti, Massimo; Nelson, Mark; Quiros-Roldan, Eugenia; Bella, Daniele; Pastore, Giuseppe; Ladisa, Nicoletta; Minoli, Lorenzo; Sotgiu, Giovanni; Mazzotta, Francesco; Lo Caputo, Sergio; Di Perri, Giovanni; Filice, Gaetano; Tinelli, Carmine; Carosi, Giampiero // BMC Infectious Diseases;2005, Vol. 5 Issue 1, p58
Background: The risk of hepatotoxicity associated with different highly active antiretroviral therapy (HAART) regimens (containing multiple-protease inhibitors, single-protease inhibitors or non nucleoside reverse transcriptase inhibitors) in HIV-HCV co-infected patients has not been fully...
- HIV-1 Protease Inhibitors Resistance Profiles in Patients with Virological Failure on LPV/r-based 2nd Line Regimen in Cambodia. Nerrienet, Eric; Nouhin, Janin; Ngin, Sopheak; Segeral, Olivier; Ken, Sreymom; Phon, Kerya; Hak, Chanroeurn; Ouk, Vara; Saphonn, Vonthanak; Ferradini, Laurent; Delfraissy, Jean-Francois // Journal of AIDS & Clinical Research;Special2012, Vol. 3 Issue S, Special section p1
Objective: To describe the ARV resistance profiles of patients experiencing virological failure after at least 6 months on LPV/r-based 2nd line regimen in Cambodia. Design: Retrospective analysis of resistance testing of 89 patients with detectable viral load under LPV/r-based 2nd line regimen....
- PEPSIN ASSAY ONE OF THE EASIEST APPROACH FOR PRESCREENING OF HIV-PROTEASE INHIBITORS. Singh, K. P.; Kumar, A.; Prasad, R. // Journal of Pharmaceutical & Scientific Innovation;Jan/Feb2013, Vol. 2 Issue 1, p53
As HIV is quickly becoming one of the world deadliest viruses, one of the biggest problem in curing AIDS is as HIV can easily develop resistance against the provided drugs. HAART (Highly active antiretroviral therapy) is the only one hope for the AIDS patients till now, which can increase the...
- Factors Associated with Poor Immunologic Responses Despite Viral Suppression in Markedly Immunosuppressed Patients. Collazos, Julio; Asensi, V�ctor; Cart�n, Jos� Antonio // AIDS Patient Care & STDs;Jun2007, Vol. 21 Issue 6, p378
To determine the factors associated with poor immunologic responses despite viral suppression in markedly immunocompromised patients (=200 CD4 cells per microliter at baseline), individuals with less than 100 CD4 increases after 12 months of nelfinavir-based highly active antiretroviral therapy...
- Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Martinez, V.; Caumes, E.; Gambotti, L.; Ittah, H.; Morini, J.-P.; Deleuze, J.; Gorin, I.; Katlama, C.; Bricaire, F.; Dupin, N. // British Journal of Cancer;4/10/2006, Vol. 94 Issue 7, p1000
Highly active antiretroviral therapy (HAART) reduces the incidence and improves the prognosis of Kaposi's sarcoma (KS). This study was designed to identify factors associated with KS clinical responses in HIV-infected patients during HAART. We reviewed the files of 138 HIV-1-infected patients...
- High Rate of Bone Thinning in People With Long Antiretroviral Treatment. // HIV Treatment ALERTS!;Mar2011, p12
The article presents a study on the effect of antiretroviral therapy on the high rate of bone thinning among HIV patients in Spain. The study found a link between low mineral density and treatment with Viread or protease inhibitors. The study also identified other risk factors for osteopenia or...
- Associations among Race/Ethnicity, ApoC-III Genotypes, and Lipids in HIV-1-Infected Individuals on Antiretroviral Therapy. Foulkes, Andrea S.; Wohl, David A.; Frank, Ian; Puleo, Elaine; Restine, Stephanie; Wolfe, Megan L.; Dube, Michael P.; Tebas, Pablo; Reilly, Muredach P. // PLoS Medicine;Mar2006, Vol. 3 Issue 3, pe52
Background: Protease inhibitors (PIs) are associated with hypertriglyceridemia and atherogenic dyslipidemia. Identifying HIV-1-infected individuals who are at increased risk of PI-related dyslipidemia will facilitate therapeutic choices that maintain viral suppression while reducing risk of...
- Diabetes, protease-inhibitor link unproved: directorate. // CMAJ: Canadian Medical Association Journal;09/01/97, Vol. 157 Issue 5, p502
States that the Therapeutic Drugs Directorate at Health Canada find no conclusive evidence to support a causal relationship between protease inhibitors and diabetes or hyperglycemia in HIV-infected patients.
- Lease on life. Larson, Laurie // AHA News;10/07/96, Vol. 32 Issue 40, p7
Discusses the therapeutic value of protease inhibitors in the battle against the virus that causes AIDS. Changes in the way hospitals are being run due to protease inhibitors; Approval of protease inhibitors by the Food and Drug Administration.
